Rk Capital Management LLC Increased Its Jazz Pharmaceuticals Plc (JAZZ) Stake as Shares Rose

June 29, 2018 - By Alex Paulin

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Corporate LogoBig Money Sentiment decreased to 1.02 in 2018 Q1. It has change of 0.07, from 2017Q4’s 1.09. The ratio dropped due to JAZZ positioning: 29 sold and 96 reduced. 44 funds acquired holdings and 84 increased holdings. Investors holded 52.98 million in 2017Q4 but now own 51.95 million shares or 1.94% less. Schwab Charles Inv Management invested in 0.03% or 218,305 shs. Twin Tree Mgmt LP invested in 0% or 112 shs. Suntrust Banks Incorporated invested in 9,004 shs or 0.01% of the stock. Renaissance Tech Limited Liability Corp has 958,400 shs. Brave Asset Mgmt Incorporated has 1,660 shs. Point72 Asset Management Ltd Partnership holds 0.03% of its capital in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 50,000 shs. Parametric Port Assoc Limited Liability stated it has 45,176 shs. 1,732 are owned by Greenwood Cap Associate Lc. Eqis Capital holds 0.06% or 8,425 shs. Barclays Public Ltd Company accumulated 14,323 shs or 0% of the stock. Renaissance Group Incorporated Limited Liability Corp has 120,893 shs for 0.62% of their capital. Regions Fincl holds 85 shs. Contravisory Management accumulated 44 shs or 0% of the stock. Unknown-based Mckinley Cap Mngmt Lc Delaware has invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Denver Advsr Limited Liability Corporation reported 2,345 shs.

JAZZ registered $5.86 million net activity with 0 insider purchases and 23 insider sales since January 12, 2018. 3,000 shs were sold by COZADD BRUCE C, worth $450,000 on Friday, January 12. On Monday, May 14 $32,936 worth of stock was sold by MILLER MICHAEL PATRICK. On Tuesday, April 10 3,899 shs were sold by WILSON KAREN J, worth $604,345. 877 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shs with value of $122,446 were sold by Treacy Paul.

Rk Capital Management Llc’s holdings in Jazz Pharmaceuticals Plc (JAZZ) is rose by 128.04% based on its latest 2018Q1 regulatory filing with the SEC. 58,900 shares were bought by Rk Capital Management Llc as the company’s stock rose 11.92% while stock markets declined. The major pharmaceuticals company at the end of 2018Q1 was priced at $15.84 million. It’s up from 46,000 at the end of the previous reported quarter. Now it had 104,900 shares held by the hedge fund . For a total of 265,700 shares it reduced its holding in Kbr Inc (NYSE:KBR) by 266,900 shares in the quarter, and has cut its stake in Penn Natl Gaming Inc (NASDAQ:PENN).

For more Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news brought out recently go to: Benzinga.com, Benzinga.com, Prnewswire.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” brought out on June 21, 2018, “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” on June 20, 2018, “Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for …” with a publish date: June 03, 2018, “Jazz Pharmaceuticals (JAZZ) PT Raised to $220 at Cowen; ‘Transitioning Growth Asset'” and the last “Key events next week – healthcare” with publication date: June 01, 2018.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

A total of 11 analysts rate Jazz Pharmaceuticals (NASDAQ:JAZZ) as follows: 10 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 91% are bullish. (NASDAQ:JAZZ) has 19 ratings reports on 29 Jun 2018 according to StockzIntelligence. On Wednesday, May 9 the stock has “Outperform” rating by BMO Capital Markets. On Monday, June 25 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Buy” rating by FBR Capital. On Friday, March 16 the firm has “Buy” rating given by Leerink Swann. On Friday, April 6 the rating was maintained by Seaport Global with “Buy”. The company rating was maintained by Cantor Fitzgerald on Monday, May 7. On Thursday, May 10 FBR Capital maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with “Buy” rating. On Tuesday, February 20 the firm has “Buy” rating by Bank of America given. On Tuesday, January 2 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given by Leerink Swann. On Tuesday, January 30 the rating was maintained by Piper Jaffray with “Buy”. On Tuesday, January 2 the firm has “Buy” rating by Stifel Nicolaus given.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.